Nomogram Estimating the Probability of Intraabdominal Abscesses after Gastrectomy in Patients with Gastric Cancer

Bang Wool Eom*, Jungnam Joo[1],*, Young-Woo Kim, Boram Park[1], Hong Man Yoon, Keun Won Ryu, and Soo Jin Kim

Gastric Cancer Branch and [1]Biometric Research Branch, Research Institute and Hospital, National Cancer Center, Goyang, Korea

Purpose: Intraabdominal abscess is one of the most common reasons for re-hospitalization after gastrectomy. This study aimed to develop a model for estimating the probability of intraabdominal abscesses that can be used during the postoperative period.

Materials and Methods: We retrospectively reviewed the clinicopathological data of 1,564 patients who underwent gastrectomy for gastric cancer between 2010 and 2012. Twenty-six related markers were analyzed, and multivariate logistic regression analysis was used to develop the probability estimation model for intraabdominal abscess. Internal validation using a bootstrap approach was employed to correct for bias, and the model was then validated using an independent dataset comprising of patients who underwent gastrectomy between January 2008 and March 2010. Discrimination and calibration abilities were checked in both datasets.

Results: The incidence of intraabdominal abscess in the development set was 7.80% (122/1,564). The surgical approach, operating time, pathologic N classification, body temperature, white blood cell count, C-reactive protein level, glucose level, and change in the hemoglobin level were significant predictors of intraabdominal abscess in the multivariate analysis. The probability estimation model that was developed on the basis of these results showed good discrimination and calibration abilities (concordance index=0.828, Hosmer-Lemeshow chi-statistic P=0.274). Finally, we combined both datasets to produce a nomogram that estimates the probability of intraabdominal abscess.

Conclusions: This nomogram can be useful for identifying patients at a high risk of intraabdominal abscess. Patients at a high risk may benefit from further evaluation or treatment before discharge.

Key Words: Stomach neoplasms; Postoperative complications; Abdominal abscess; Nomograms

Introduction

Radical gastrectomy with lymph node dissection in patients with gastric cancer has been associated with a high rate of postoperative complications, ranging from 20% to 46%.[1-4] Accumulated surgical experience and recent advances in surgical instruments and perioperative management have led to a reduction in postoperative morbidity and mortality.[5-9] However, despite these advances, major complications, particularly in high-risk patients, remain problematic.

Intraabdominal abscess is one of the most commonly reported post-gastrectomy complications. The incidence of intraabdominal abscess, manifesting as complex fluid collection on computed tomography (CT), abdominal pain, fever, and leukocytosis, ranges from 0.6% to 17%.[1,3,7,8,10] The abscess is usually detected within several days of surgery, and immediate intervention is possible if the patient is still hospitalized. However, there are patients who present to the emergency department with delayed intraabdominal abscess after an uneventful discharge. With the recent introduction of the enhanced recovery after surgery pathway hospital stays are shorter, and fewer

Correspondence to: Young-Woo Kim
Gastric Cancer Branch, Research Institute and Hospital, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea
Tel: +82-31-920-1635, Fax: +82-31-920-0696
E-mail: gskim@ncc.re.kr
*These authors contributed equally to this paper as co-first authors.

intraabdominal abscesses after discharge has been reported.[11-14] Therefore, accurate identification of clinical findings indicative of a higher probability of intraabdominal abscess, which could prompt further evaluation and treatment before discharge, would be helpful.

This study aimed to identify clinical and laboratory markers associated with intraabdominal abscess in patients who have undergone gastrectomy for gastric cancer and to develop a model for estimating the probability of intraabdominal abscess based on multivariate analysis.

Materials and Methods

1. Study cohort

The study cohort (development set) consisted of 1,564 patients who underwent curative gastrectomy for gastric cancer in the National Cancer Center, Korea, from April 2010 to June 2012. We adopted all surgical approaches: open gastrectomy and laparoscopic or robot-assisted gastrectomy, regardless of the extent of the surgery (subtotal or total gastrectomy). In patients with early gastric cancer, more than D1+ lymph node dissection was performed, and in those with more advanced tumors, more than D2 lymph node dissection was performed, in accordance with the Japanese Gastric Cancer Association guideline.[15]

An independent cohort comprising of 1,508 patients who underwent gastrectomy for gastric cancer from January 2008 to March 2010 was used as a validation set to evaluate the performance of the development model. The inclusion and exclusion criteria for the validation set were the same as those for the development set.

Patients generally received in-hospital postoperative care for 5 to 7 days after surgery, and laboratory tests were conducted on postoperative days 1, 3, 5, and 7. After discharge, the patients visited the outpatient clinic within 1 month for short-term evaluation. Regular follow-up was then performed for 5 years. The last follow-up days were August 31, 2012, and December 31, 2013, in the development and validation sets, respectively.

This study was approved by the Institutional Review Board at the National Cancer Center (No. NCCNCS-13-786).

2. Definition of intraabdominal abscess

An intraabdominal abscess was defined by the following three conditions: 1) Appearance of an extra-luminal fluid collection on a postoperative abdominal CT scan; 2) Absence of any other infection focus on the abdominal CT scan; 3) Record of treatments such as antibiotics and/or surgical, endoscopic, and radiological intervention provided because of moderate or severe complications, according to the Accordion Severity Grading System of Surgical Complications.[16] Clinically insignificant fluid collections not requiring treatment were excluded from the analysis.

3. Clinicopathological variables

All clinical variables suspected to be associated with intraabdominal abscess, including age, sex, body mass index (BMI), comorbidities, surgical approach, extent of gastrectomy, extent of lymph node dissection, combined operation, operating time, pathological stage, number of antibiotics used, and transfusion, were analyzed in both cohorts, along with postoperative vital signs, inflammation-related laboratory values (i.e., white blood cell [WBC] count, segmented neutrophils, C-reactive protein [CRP], total bilirubin [T. bil], glucose, serum amylase), and change in hemoglobin level (HbD) from the preoperative period to postoperative day 5 or 7. The highest values recorded during the hospital period were used, and the tumor stage was defined according to the American Joint Committee on Cancer staging system, 7th edition.[17]

4. Statistical analysis

All continuous variables are presented as means±standard deviation, and categorical variables are shown as proportions. Distribution differences were tested using the chi-square test for categorical variables and the t-test for continuous variables.

Logistic regression with intraabdominal abscess as an outcome was carried out for both the univariate and multivariate analyses. Univariate analyses were separately conducted for 26 potentially related factors, and all variables were then included in the multivariate model. The final risk estimation model was formulated on the basis of backward variable selection, with an elimination criterion of $P>0.05$. Adjacent categories of certain categorical variables, such as serum amylase, were grouped together when decreasing odds ratios were observed for increasing values of related factors. The performance of the model was then evaluated in terms of discrimination and calibration. For discrimination, we examined the receiver operating characteristics curve (ROC) and associated area under the ROC curve (AUC), and to test calibration, we used the Hosmer-Lemeshow (HL) chi-square statistic.

Internal validation using a bootstrap approach was then employed to correct biases.[18] In this approach, random samples of the same sample size were drawn from the original dataset with replacement to form a bootstrap sample. The same model-building technique was used on the bootstrap samples. This bootstrap resampling procedure was repeated 2,000 times to obtain the average bias, which provided a bias-corrected estimate for performance measures. The risk estimation model was then applied to the validation set to examine the performance of the model on independent data. When the performance was acceptable, the same procedure was performed for the entire dataset (development and validation sets).[19]

Data analyses were performed using SAS ver. 9 (SAS Institute Inc., Cary, NC, USA), and R software (ver. 2.12.1). All reported P-values are two-sided.

Results

1. Clinicopathological characteristics in the development and validation datasets

The incidence of intraabdominal abscess was 7.80% (122/1,564) in the development set and 7.76% (117/1,508) in the validation set. Among patients in the abscess group of the development set, 65 patients (53.3%) were diagnosed with the abscess during hospitalization and 43 patients (35.2%) presented to the emergency department with abscess after discharge. Intraabdominal abscess was detected incidentally during prechemotherapy CT scans at 3 to 5 weeks postoperatively in 14 patients (11.5%).

Patient characteristics and clinicopathological features were compared between abscess and non-abscess groups in both datasets (Supplement 1). In the development dataset, patients in the abscess group were older and had higher BMI and prolonged operating times, compared with the patients in the non-abscess group. The abscess group had a greater number of male patients, and the numbers of open surgeries, total gastrectomies, combined operations, transfusions, and advanced pT and pN stages were higher. Similar results were noted in the validation set, and significant differences were observed for sex, incidence of hypertension, extent of gastrectomy, combined operation, operating time, numbers of antibiotics used, transfusion, and pT.

In terms of postoperative vital signs and inflammation-related laboratory data (Supplement 1), in the development set, fever; elevated heart rate, WBC count, segment neutrophil count,

and CRP; T. bil; glucose; and amylase levels; along with greater values of HbD were associated with abscess, and the validation set showed comparable results with the development set.

## 2. Development of the risk estimation model

Univariate and multivariate logistic regression analyses were first performed using the development dataset (Table 1). The apparent discrimination and calibration performances were good, with AUC=0.828 (95% confidence interval [CI], 0.788~0.868) and HL chi-square test statistic=3.888 with P=0.274 (Fig. 1). After bias correction with 2,000 cycles of bootstrap resampling, the bias-corrected AUC was 0.801, and the HL chi-square test statistic was 5.511 with P=0.138, which implied a good value.

The risk estimation model for probability of intraabdominal abscess formulated using the development set was then applied to the independent validation set. The AUC was 0.791 (95%

Table 1. Multivariate logistic regression analysis using the development set

Characteristic	Subgroup	Odds ratio (95% CI)	P-value
Surgical approach	Laparoscopy/ robot	1	
	Open	1.76 (1.11~2.81)	0.017
Operating time (min)		1.01 (1.00~1.01)	<0.001
pN	0	1	
	1	1.70 (0.94~3.09)	0.079
	2, 3	1.75 (1.07~2.86)	0.026
Body temperature (℃)*	<37.8	1	
	≥37.8	2.22 (1.44~3.42)	<0.001
WBC (/μl)*	<12	1	
	12~14.9	1.66 (1.04~2.63)	0.033
	≥15	2.10 (1.18~3.74)	0.012
CRP (mg/dl)*	<10	1	
	10~14.9	1.10 (0.50~2.41)	0.817
	15~19.9	1.78 (0.83~3.82)	0.139
	≥20	4.52 (2.18~9.36)	<0.001
Glucose (mg/dl)*	<150	1	
	150~199	1.18 (0.74~1.88)	0.493
	≥200	2.34 (1.36~4.00)	0.002
Hemoglobin difference (g/dl)	<3	1	
	≥3	1.89 (1.23~2.90)	0.004

CI = confidence interval; WBC = white blood cell count; CRP = C-reactive protein. *The highest values for the vital signs and inflammatory markers were used in the analysis.

Fig. 1. Receiever-operator characteristic curve and calibration plots of the prediction model for the development dataset and the entire (development and validation) dataset. AUC = area under the receiver operating characteristics curve; CI = confidence interval.

CI, 0.751~0.832), and the HL chi-square result was 18.286 with P=0.001. Although the calibration was slightly off, it showed good discrimination, and the AUC was close to the value expected by internal validation.

3. Final model using the total dataset

Because the model development procedure was validated, we used the total dataset (development and validation sets) to generate the final risk estimation model. The multivariate analysis identified the extent of gastrectomy, operating time, transfusion, pT, temperature, WBC count, segmented neutrophils, CRP and amylase levels, and HbD as independent risk factors for intraabdominal abscess (Table 2).

4. Development of the nomogram

We created a nomogram that estimates the risk of intraabdominal abscess on the basis of the final risk estimation model

(Fig. 2). Points are assigned for each factor, and the sum of the points for all factors included in the model is obtained and corresponds to the estimated probability of the development of an intraabdominal abscess after gastrectomy. Considering that the incidence of intraabdominal abscess was approximately 7.8% in this study, we calculated the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for each cut-off value between 6 and 9% in 0.5% increments (Table 3). For example, if a patient has an estimated probability of intraabdominal abscess of >7.5%, we can expect approximately 75.3% sensitivity, 74.3% specificity, 19.8% PPV, and 97.3% NPV for postoperative intraabdominal abscess.

Discussion

Intraabdominal abscess is one of the most common reasons for an early visit to the emergency department after gastrectomy.

Table 2. Multivariate logistic regression using the total dataset

Characteristic	Subgroup	Odds ratio (95% CI)	P-value
Extent of gastrectomy	Subtotal	1	
	Total	1.60 (1.18~2.18)	0.003
Operating time (min)		1.00 (1.00~1.01)	0.005
Postoperative transfusion	Absent	1	
	Present	2.25 (1.36~3.75)	0.002
pT	1	1	
	2, 3	1.53 (1.10~2.13)	0.011
	4	1.93 (1.29~2.91)	0.002
Body temperature (°C)*	<37.8	1	
	≥37.8	2.32 (1.72~3.13)	<0.001
WBC (/μl)*	<12	1	
	12~14.9	1.53 (1.06~2.21)	0.021
	≥15	1.54 (1.07~2.22)	0.012
Seg neutrophil (%)*	<75	1	
	75~84.9	1.79 (1.13~2.83)	0.013
	≥85	2.72 (1.62~4.56)	<0.001
CRP (mg/dl)*	<10	1	
	10~14.9	1.57 (0.93~2.65)	0.095
	15~19.9	2.85 (1.73~4.71)	<0.001
	≥20	5.40 (3.35~8.70)	<0.001
Amylase (U/L)*	1~200	1	
	≥200	1.80 (1.31~2.47)	<0.001
Hemoglobin difference (g/dl)	<3	1	
	≥3	1.65 (1.22~2.23)	0.001

CI = confidence interval; WBC = white blood cell count; CRP = C-reactive protein. *The hightest values for the vital signs and inflammatory markers were used in the analysis.

Some patients who are symptom-free at the time of discharge develop abdominal pain or fever within several days after discharge, and only then is an intraabdominal abscess detected. In this study, we developed a nomogram to estimate the probability of intraabdominal abscess on the basis of postoperative clinical findings. A physician can use the nomogram to check the probability of intraabdominal abscess before discharging the patient, and may choose to perform further evaluation or treatment if the patient has a high probability of developing abscess.

There are several useful scoring systems for predicting clinical outcomes, including the Sequential Organ Failure Assessment, the Acute Physiology and Chronic Health Evaluation II scoring system, the Simplified Acute Physiology Score II, and the Physiological and Operative Severity Score for the enUmeration of Mortality and Morbidity (POSSUM).[20-23] Among these scoring systems, POSSUM has been validated in various surgical fields, and a nomogram based on POSSUM has been recently developed.[24-27] However, these scoring systems are used to predict general morbidity or mortality, whereas our nomogram is solely focused on the risk of intraabdominal abscess after gastrectomy in patients with gastric cancer.

Risk factors for post-gastrectomy complications have been well reported, and include older age, male sex, presence of comorbidities, advanced tumor stage, open surgical approach, extended lymph node dissection, combined resection, and prolonged operating time.[28-32] In terms of intraabdominal abscess in particular, Lo et al.[33] reported that the predisposing factors include age, prolonged operating time, and combined organ resection. While previous studies have identified risk factors according to baseline or preoperative findings to predict complications in the early postoperative period, our study was performed to estimate the probability of intraabdominal abscess in patients who are ready for discharge. Therefore, we included not only preoperative baseline factors but also postoperative vital signs and laboratory findings in our analyses.

One of the potential benefits of our nomogram is the prevention of delayed sepsis. Intraabdominal abscesses that are detected in a timely fashion are readily treated with antibiotics, percutaneous drainage, or both.[33] By contrast, delayed detection of an abscess can result in sepsis or associated complications including pseudoaneurysm, and the long-term sequelae may be irreversible. Because our nomogram predicts the probability of intraabdominal abscess, the physician can perform additional tests and render necessary treatment before discharging the patient, and delayed sepsis might be prevented. This could also contribute to reduced hospital costs, which are high when patients are readmitted with postoperative infections.[34-36] In one Swedish study, the cost of readmission for small bowel obstruction was approximately equal to that of gastric cancer treatment.[37] Another potential benefit is the limitation of abdominal CT scanning to only those patients with a high probability of abscess, which would further contribute to the reduction of hospital costs.

Larger datasets provide better estimates of the effect of each factor once a procedure for developing a risk estimation model is validated by using acceptable performance. Therefore, we evaluated models from both the development dataset and the total dataset, and found that there was some variation in significant factors. In the model using the total dataset, surgical approach,

Fig. 2. A nomogram estimating the probability of developing intraabdominal abscess after gastrectomy. OP = operative; WBC = white blood cell; CRP = C-reactive protein; Hb = hemoglobin.

Table 3. Sensitivity, specificity, PPV, and NPV of predicted probability using the nomogram for cut off points from 6% to 9% (increments of 0.5%)

Predicted probability (%)	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
6.0	78.7	69.5	17.9	97.5
6.5	77.0	71.3	18.5	97.3
7.0	76.2	72.8	19.1	97.3
7.5	75.3	74.3	19.8	97.3
8.0	74.1	75.9	20.6	97.2
8.5	73.2	77.4	21.4	97.2
9.0	72.4	78.5	22.1	97.1

PPV = positive predictive value; NPV = negative predictive value.

pN, and glucose were replaced with the extent of gastrectomy, pT, neutrophil count, amylase level, and transfusion. When we performed internal validation by bootstrapping, we found that significant risk factors were frequently matched with those in the total dataset, and we therefore decided to develop our nomogram on the basis of the total dataset. This method provided better statistical accuracy for estimating the effects of each factor.

Once we generated an acceptable risk prediction model, we checked its discrimination and calibration abilities. Discrimination accounts for the probability of a model producing higher risk estimates for patients who develop intraabdominal abscess than it does for those who do not, and calibration determines how closely the estimated probabilities match the observed probabilities. We used the bootstrap approach for internal validation because bias occurs when discrimination and calibration are calculated on the basis of a development dataset. The difference between performance measures in the model for the bootstrap samples and the original dataset represents the bias indicating over-fitting, and the bias-corrected measure indicates how well the model will perform on an external independent dataset.

In producing our model, we defined all cases of fluid collection as intraabdominal abscess, and there were some patients who had both fluid collection (abscess) and anastomotic leakage. In the development dataset, among 122 patients in the abscess group, 17 (13.9%) had CT findings of probable anastomotic leakage and 14 underwent further evaluations such as an endoscopy and upper gastrointestinal series, 3 (2.5%) of whom had confirmed anastomotic leakage. Further, there were 8 of 16 patients without any suggestion of leakage on CT scan who were diagnosed with leakage by other means. In total, there were 11 patients (11/122, 9.0%) in the abscess group of the development dataset who had anastomotic leaks, suggesting that a more thorough evaluation for this complication may be necessary.

The incidence of intraabdominal abscess after gastrectomy

in gastric cancer patients may be affected by various additional factors, including surgeon, institution and tumor location. Therefore, evaluating our nomogram by using patient data from other institutions will be necessary. Additionally, the present study was performed using retrospectively collected data, and there may be selection, information, and measurement biases. However, we believe these biases had a weak influence on the results because all variables were objective values, and there was little missing data.

In conclusion, we have developed a nomogram for estimating the risk of intraabdominal abscess after gastrectomy in gastric cancer patients. The availability of a calculated probability for the development of intraabdominal abscess may help a physician decide whether further evaluation or treatment should be ordered before a patient is discharged. Additional external validation using a multicenter dataset will be useful to generalize the utility of the nomogram.

Acknowledgments

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Electronic Supplementary Material

The online version of this article (doi: 10.5230/jgc.2015.15.4.262) contains supplementary materials.

References

1. Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995;345:745-748.
2. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, et al; The Surgical Cooperative Group. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. Lancet 1996;347:995-999.
3. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy: Japan Clinical Oncology Group study 9501. J Clin Oncol 2004;22:2767-2773.
4. Zilberstein B, Martins BC, Jacob CE, Bresciani C, Lopasso FP, de Cleva R, et al. Complications of gastrectomy with lymphadenectomy in gastric cancer. Gastric Cancer 2004;7:254-259.
5. Ryu KW, Kim YW, Lee JH, Nam BH, Kook MC, Choi IJ, et al. Surgical complications and the risk factors of laparoscopy-assisted distal gastrectomy in early gastric cancer. Ann Surg Oncol 2008;15:1625-1631.
6. Ahn CW, Hur H, Han SU, Cho YK. Comparison of intracorporeal reconstruction after laparoscopic distal gastrectomy with extracorporeal reconstruction in the view of learning curve. J Gastric Cancer 2013;13:34-43.
7. Kim KM, An JY, Kim HI, Cheong JH, Hyung WJ, Noh SH. Major early complications following open, laparoscopic and robotic gastrectomy. Br J Surg 2012;99:1681-1687.
8. Kim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report: a phase III multicenter, prospective, randomized Trial (KLASS Trial). Ann Surg 2010;251:417-420.
9. Kim YW, Yoon HM, Eom BW, Park JY. History of minimally invasive surgery for gastric cancer in Korea. J Gastric Cancer 2012;12:13-17.
10. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Shia LT, Whang-Peng J. Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Br J Surg 2004;91:283-287.
11. Tang J, Humes DJ, Gemmil E, Welch NT, Parsons SL, Catton JA. Reduction in length of stay for patients undergoing oesophageal and gastric resections with implementation of enhanced recovery packages. Ann R Coll Surg Engl 2013;95:323-328.
12. Grantcharov TP, Kehlet H. Laparoscopic gastric surgery in an enhanced recovery programme. Br J Surg 2010;97:1547-1551.
13. So JB, Lim ZL, Lin HA, Ti TK. Reduction of hospital stay and cost after the implementation of a clinical pathway for radical gastrectomy for gastric cancer. Gastric Cancer 2008;11:81-85.
14. Choi JW, Xuan Y, Hur H, Byun CS, Han SU, Cho YK. Out-

comes of critical pathway in laparoscopic and open surgical treatments for gastric cancer patients: patients selection for fast-track program through retrospective analysis. J Gastric Cancer 2013;13:98-105.

15. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011;14:113-123.

16. Strasberg SM, Linehan DC, Hawkins WG. The accordion severity grading system of surgical complications. Ann Surg 2009;250:177-186.

17. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Handbook. 7th ed. New York: Springer-Verlag, 2010.

18. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387.

19. Simon R. Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data. Br J Cancer 2003;89:1599-1604.

20. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al; On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996;22:707-710.

21. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-829.

22. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-2963.

23. Copeland GP, Jones D, Walters M. POSSUM: a scoring system for surgical audit. Br J Surg 1991;78:355-360.

24. Wijesinghe LD, Mahmood T, Scott DJ, Berridge DC, Kent PJ, Kester RC. Comparison of POSSUM and the Portsmouth predictor equation for predicting death following vascular surgery. Br J Surg 1998;85:209-212.

25. Sagar PM, Hartley MN, MacFie J, Taylor BA, Copeland GP. Comparison of individual surgeon's performance. Risk-adjusted analysis with POSSUM scoring system. Dis Colon Rectum 1996;39:654-658.

26. Neary B, Whitman B, Foy C, Heather BP, Earnshaw JJ. Value of POSSUM physiology scoring to assess outcome after intra-arterial thrombolysis for acute leg ischaemia (short note). Br J Surg 2001;88:1344-1345.

27. Williams DJ, Walker JD. A nomogram to calculate the Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM). Br J Surg 2014;101:239-245.

28. Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004;22:2069-2077.

29. Park DJ, Lee HJ, Kim HH, Yang HK, Lee KU, Choe KJ. Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg 2005;92:1099-1102.

30. Seo SH, Hur H, An CW, Yi X, Kim JY, Han SU, et al. Operative risk factors in gastric cancer surgery for elderly patients. J Gastric Cancer 2011;11:116-121.

31. Lee JH, Park do J, Kim HH, Lee HJ, Yang HK. Comparison of complications after laparoscopy-assisted distal gastrectomy and open distal gastrectomy for gastric cancer using the Clavien-Dindo classification. Surg Endosc 2012;26:1287-1295.

32. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Crose N, et al; The Italian Gastrointestinal Tumor Study Group. Total versus subtotal gastrectomy: surgical morbidity and mortality rates in a multicenter Italian randomized trial. Ann Surg 1997;226:613-620.

33. Lo CH, Chen JH, Wu CW, Lo SS, Hsieh MC, Lui WY. Risk factors and management of intra-abdominal infection after extended radical gastrectomy. Am J Surg 2008;196:741-745.

34. Miletic KG, Taylor TN, Martin ET, Vaidya R, Kaye KS. Readmissions after diagnosis of surgical site infection following knee and hip arthroplasty. Infect Control Hosp Epidemiol 2014;35:152-157.

35. Avritscher EB, Cooksley CD, Rolston KV, Swint JM, Delclos GL, Franzini L, et al. Serious postoperative infections following resection of common solid tumors: outcomes, costs, and impact of hospital surgical volume. Support Care Cancer 2014;22:527-535.

36. Keller DS, Swendseid B, Khorgami Z, Champagne BJ, Reynolds HL Jr, Stein SL, et al. Predicting the unpredictable: comparing readmitted versus non-readmitted colorectal surgery patients. Am J Surg 2014;207:346-351; discussion 350-351.

37. Tingstedt B, Isaksson J, Andersson R. Long-term follow-up and cost analysis following surgery for small bowel obstruction caused by intra-abdominal adhesions. Br J Surg 2007;94:743-748.

Supplement 1. Patient characteristics, clinicopathological features, postoperative vital signs, and inflammation-related laboratory findings in the development and validation datasets

Characteristic	Subgroup	Development set (n = 1564)			Validation set (n = 1508)		
		No abscess (%) (n = 1442)	Abscess (%) (n = 122)	P	Non-abscess (%) (n = 1391)	Abscess (%) (n = 117)	P
Age (mean ± SD)		58.5±12.0	61.5±11.3	0.009	58.2±11.9	60.4±12.0	0.055
Sex	Male	942 (65.3)	99 (81.1)	<0.001	906 (65.1)	94 (80.3)	0.001
	Female	500 (34.7)	23 (18.8)		485 (34.9)	23 (19.7)	
BMI (kg/m^2) (mean ± SD)		23.7±3.1	24.4±3.5	0.013	23.6±3.2	23.8±3.0	0.462
Diabetes mellitus	Absent	1234 (85.6)	101 (82.8)	0.403	1226 (88.1)	101 (86.3)	0.562
	Present	208 (14.4)	21 (17.2)		165 (11.9)	16 (13.7)	
Hypertension	Absent	974 (67.5)	75 (61.5)	0.171	1011 (72.7)	73 (62.4)	0.017
	Present	468 (32.5)	47 (38.5)		380 (27.3)	44 (37.6)	
Heart disease	Absent	1332 (92.3)	109 (89.3)	0.233	1347 (96.8)	113 (96.6)	0.784
	Present	110 (7.6)	13 (10.7)		44 (3.2)	4 (3.4)	
Liver disease	Absent	1364 (94.6)	118 (96.7)	0.311	1242 (89.3)	104 (88.9)	0.893
	Present	78 (5.4)	4 (3.2)		149 (10.7)	13 (11.1)	
Pulmonary disease	Absent	1407 (97.6)	116 (95.1)	0.128	1370 (98.5)	115 (98.3)	0.698
	Present	35 (2.4)	6 (4.9)		21 (1.5)	2 (1.7)	
Surgical approach	Open	661 (45.8)	84 (68.9)	<0.001	802 (57.7)	81 (69.2)	0.015
	Laparoscopy /Robot	781 (54.2)	38 (31.1)		589 (42.3)	36 (30.8)	
Extent of gastrectomy	Subtotal	1065 (73.9)	76 (62.3)	0.006	1029 (74.0)	50 (42.7)	<0.001
	Total	377 (26.1)	46 (37.7)		362 (26.0)	67 (57.3)	
LN dissection	D1+	127 (8.8)	6 (4.9)	0.139	88 (6.3)	4 (3.4)	0.207
	D2	1315 (91.2)	116 (95.1)		1303 (93.7)	113 (96.6)	
Combined operation	Absent	1305 (90.5)	95 (77.9)	<0.001	1344 (96.6)	99 (84.6)	<0.001
	Present	137 (9.5)	27 (22.1)		47 (3.4)	18 (15.4)	
Operating time (mean ± SD)		177.3±64.1	214.4±84.8	<0.001	187.1±71.8	212.9±102.4	0.009
Number of Antibiotics usage	1–2	1434 (99.4)	120 (98.4)	0.18	145 (10.4)	20 (17.1)	0.026
	≥3	8 (0.6)	2 (1.6)		1246 (89.6)	97 (82.9)	
Postoperative transfusion	Absent	1402 (97.2)	111 (91.0)	0.001	1332 (95.8)	97 (82.9)	<0.001
	Present	40 (2.8)	11 (9.0)		59 (4.2)	20 (17.1)	
pT	1	915 (63.5)	52 (42.6)	<0.001	742 (53.3)	45 (38.5)	0.001
	2,3	381 (26.4)	43 (35.2)		469 (33.7)	45 (38.5)	
	4	146 (10.1)	27 (22.1)		180 (12.9)	27 (23.1)	
pN	0	994 (68.9)	61 (50.0)	<0.001	893 (64.2)	67 (57.3)	0.084

	1	167 (11.6)	20 (16.4)		173 (12.4)	12 (10.3)	
	2,3	281 (19.5)	41 (33.6)		325 (23.4)	38 (32.5)	
*Body temperature (°C)	<37.8	1106 (76.7)	51 (41.8)	<0.001	1042 (74.9)	49 (41.9)	<0.001
	≥37.8	336 (23.3)	71 (58.2)		349 (25.1)	68 (58.1)	
*Pulse rate	<100	1035 (71.8)	62 (50.8)	<0.001	1044 (75.1)	48 (41.0)	<0.001
	100–119	338 (23.4)	41 (33.6)		299 (21.5)	55 (47.0)	
	≥120	69 (4.8)	19 (15.6)		48 (3.5)	14 (12.0)	
*WBC (/μℓ)	<12	990 (68.7)	51 (41.8)	<0.001	385 (27.7)	16 (13.7)	0.002
	12–14.9	334 (23.2)	43 (35.2)		430 (30.9)	36 (30.8)	
	≥15	118 (8.2)	28 (23.0)		576 (41.4)	65 (55.6)	
*Seg neutrophil (%)	<75	393 (27.3)	15 (12.3)	<0.001	351 (25.2)	10 (8.5)	<0.001
	75–84.9	884 (61.3)	68 (55.7)		879 (63.2)	67 (57.3)	
	≥85	165 (11.4)	39 (32.0)		161 (11.6)	40 (34.2)	
*CRP (mg/dL)	<10	479 (33.2)	11 (9.0)	<0.001	576 (41.4)	14 (12.0)	<0.001
	10–14.9	430 (29.8)	20 (16.4)		357 (25.7)	19 (16.2)	
	15–19.9	300 (20.8)	26 (21.3)		258 (18.5)	34 (29.1)	
	≥20	233 (16.2)	65 (53.3)		200 (14.4)	50 (42.7)	
*T. bil (mg/dL)	<1.2	834 (57.8)	51 (41.8)	<0.001	813 (58.4)	60 (51.3)	0.196
	1.2–2.9	584 (40.5)	64 (52.5)		545 (39.2)	52 (44.4)	
	≥3	24 (1.7)	7 (5.7)		33 (2.4)	5 (4.2)	
*Glucose (mg/dL)	<150	834 (57.8)	49 (40.2)	<0.001	413 (29.7)	23 (19.7)	0.003
	150–199	450 (31.2)	41 (33.6)		755 (54.3)	62 (53.0)	
	≥200	158 (11.0)	32 (26.2)		223 (16.0)	32 (27.4)	
*Amylase (U/)	<100	800 (55.5)	52 (42.6)	<0.001	629 (45.2)	31 (26.5)	<0.001
	101–200	440 (30.5)	36 (29.5)		461 (33.1)	34 (29.1)	
	>201	202 (14.0)	34 (27.9)		301 (21.6)	52 (44.4)	
Hemoglobin difference (g/dL)	<3	1135 (87.7)	61 (50.0)	<0.001	884 (63.6)	54 (46.2)	<0.001
	≥3	307 (21.3)	61 (50.0)		507 (36.5)	63 (53.8)	

SD, standard deviation; BMI, body mass index; LN, lymph node; WBC, white blood cell count; CRP, C-reactive protein; T. bil, total bilirubin.
* The highest values for the vital signs and inflammatory markers were used in the analysis.